Karyopharm Therapeutics
KPTI
77 hedge funds and large institutions have $102M invested in Karyopharm Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 15 closing their positions.
256% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 9
85% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $16.9M
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
47% more capital invested
Capital invested by funds: $69.6M → $102M (+$32.6M)
43.31% more ownership
Funds ownership: 55.52% → 98.83% (+43%)
12% more funds holding
Funds holding: 69 → 77 (+8)
Top Buyers
| 1 |
CC
Commodore Capital
New York
|
+$14.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.6M |
| 4 |
Goldman Sachs
New York
|
+$7.22M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.04M |
Top Sellers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.84M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$2.97M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$2.23M |
| 4 |
EAM
Exome Asset Management
New York
|
-$2.18M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.04M |
KPTI Hedge Fund Activity: Q1 2026 in Review
77 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2026, worth a combined $102M — up 47% from $69.6M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KPTI positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 9 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.84M sold.
- 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2026, up from 69 in Q4 2025.
- Funds reported $102M of Karyopharm Therapeutics stock for Q1 2026, up 47% quarter-over-quarter.
- 25 funds opened new Karyopharm Therapeutics positions in Q1 2026 and 15 closed out, a net change of +10 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2026 was Commodore Capital, an estimated $14.9M added.
- The largest Karyopharm Therapeutics seller in Q1 2026 was Opaleye Management, an estimated $6.84M sold.
Based on aggregated 13F filings for Q1 2026.